Abstract
In the estimated rates of European cancer incidence and mortality rates in 2012, prostate cancer ranks third in incidence (359,900) but drops to the fifth place in mortality (71.0) in the European Union (EU-27) [1].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ferlay J, Steliarov-Foucher E, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.
Bolla M, Van Poppel H. Management of prostate cancer. Berlin: Springer; 2016: in press.
Rich AR. On frequency of occurrence of occult carcinoma of the prostate. J Urol. 1935;33:215–23.
UICC. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell; 2016. ISBN 978-1-4443-3241-4.
Richard J. Ablin with professional writer Roland Rana. The great prostate hoax. New York: Palgrave McMillan; 2014. ISBN 9781137278746.
Epstein JI, Zelefsky MJ, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69:428–35.
Renehan AG, Soerjomataram I, et al. Implementing cancer prevention in Europe. Eur J Cancer. 2010;46(14):2523–4.
Griffiths K, Adlerkrenz H, et al. Nutrition and cancer. Oxford: Printek Bilbao; 1996. ISBN: 1-899-066-349.
Khayat D. Prévenir le cancer, ça depend aussi de vous. Paris: Odile Jacon; 2014. ISBN 978-2-7381-2924-6.
Bourke L, Smith D, et al. Exercise for men with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69(4):693–703.
Welch HG. Should I be tested for cancer? Maybe not and here’s why. Berkeley: Regents of the University of California. 2004. ISBN 0-520-23976-8.
Schröder FH, Hugosson J, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(3):1320–8.
Newcomb LF, Thompson IM, et al. Outcomes of active surveillance for clinically localized prostate cancer in the prospective, multi-institutional Canary PASS cohort. J Urol. 2016;195:313–20.
Nesbit RM, Plumb RT. Prostatic carcinoma. A follow-up on 795 patients treated prior to the endocrine era and a comparison of survival rates between these and patients treated by endocrine therapy. Presented at the 3rd annual meeting of the Central Surgical Association, Chicago, 1946.
Studer UE, Colette L, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol. 2008;53:941–9.
Moyad MA, Roack M. Promoting wellness for patients on androgen deprivation therapy: why using numerous drugs for drug side effects should not be first-line treatment. Urol Clin North Am. 2011;38:303–12.
Hussain M, Tangen C, et al. Evaluating intermittent androgen-deprivation therapy phase III clinical trials: the devil is in the details. J Clin Oncol. 2016;34(3):280–5.
Valdagni R, Albers P, et al. The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology. Eur J Cancer. 2011;47(1):1–7.
Hudson T, Denis L. Europa Uomo, the European Prostate Cancer Coalition. In: Ramon J, Denis L, editors. Recent results in cancer research. Berlin: Springer; 2006.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Denis, L.J. (2017). The Millenium Patients’ Perspective. In: Bolla, M., van Poppel, H. (eds) Management of Prostate Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-42769-0_27
Download citation
DOI: https://doi.org/10.1007/978-3-319-42769-0_27
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42768-3
Online ISBN: 978-3-319-42769-0
eBook Packages: MedicineMedicine (R0)